CD5 labeling of thymic carcinomas and other nonlymphoid neoplasms

We studied 109 thymic tumors and 423 other neoplasms for immunocytochemical expression of CD5 in paraffin-embedded tissue using 2 monoclonal antibodies. One of the antibodies (clone CD5/54/B4) labeled 7 (29%) of 24 thymic carcinomas but did not stain any of the other neoplasms. In contrast, the othe...

Full description

Saved in:
Bibliographic Details
Published inAmerican journal of clinical pathology Vol. 109; no. 6; pp. 722 - 726
Main Authors KORNSTEIN, M. J, ROSAI, J
Format Journal Article
LanguageEnglish
Published Chicago, IL American Society of Clinical Pathologists 01.06.1998
Subjects
Antibodies, Monoclonal
Biological and medical sciences
CD5 Antigens - analysis
Cell Membrane - immunology
Cytoplasm - immunology
Epithelial Cells - immunology
Humans
Immunoenzyme Techniques
Investigative techniques, diagnostic techniques (general aspects)
Lymphoma - immunology
Medical sciences
Miscellaneous. Technology
Paraffin
Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques
Thymoma - immunology
Thymus Neoplasms - immunology
Tissue Embedding
Human
Immunohistochemistry
Carcinoma
Thymus gland
Mediastinum disease
Malignant hemopathy
Malignant tumor
Monoclonal antibody
Lymphoma
Differential diagnostic
Thymus pathology
Pathology
Lymphoproliferative syndrome
Technique
Malignant thymoma
Comparative study
Online AccessGet full text

Cover

More Information
Summary:We studied 109 thymic tumors and 423 other neoplasms for immunocytochemical expression of CD5 in paraffin-embedded tissue using 2 monoclonal antibodies. One of the antibodies (clone CD5/54/B4) labeled 7 (29%) of 24 thymic carcinomas but did not stain any of the other neoplasms. In contrast, the other antibody (clone 4C7) labeled 15 (62%) of 24 thymic carcinomas, 2 (2%) of 84 thymomas, 3 (8%) of 37 lymphomas, and 14 (4%) of 386 other tumors. Among the lymphomas, 4C7 labeled 2 of 4 peripheral T-cell lymphomas and 1 of 4 anaplastic large cell lymphomas. Clone 4C7 produced strong labeling of reactive T lymphocytes, whereas CD5/54/B4 staining of these cells was weak or absent. No other normal cells seemed to stain with either antibody. In conclusion, one CD5 antibody clone (CD5/54/B4) specifically identified 30% of thymic carcinomas. The other CD5 antibody (clone 4C7) identified 62% of thymic carcinomas but also labeled occasional other neoplasms.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0002-9173
1943-7722
DOI:10.1093/ajcp/109.6.722